TERRI SCHMIDT: Open Payments
NPI 1992931612 · SPARKS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,839 in 89 payments from 20 companies in 2025. Trend: 2023 $1,630 · 2024 $1,795 · 2025 $1,839
Food & beverage: $1,839
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $354 |
| AstraZeneca Pharmaceuticals LP | 14 | $321 |
| PFIZER INC. | 12 | $234 |
| Amgen Inc. | 9 | $182 |
| Novo Nordisk Inc | 8 | $172 |
| Otsuka America Pharmaceutical, Inc. | 4 | $92 |
| GlaxoSmithKline, LLC. | 4 | $88 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $65 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $47 |
| Merck Sharp & Dohme LLC | 2 | $45 |
Products named: VRAYLAR, BREZTRI, NURTEC ODT, OTEZLA, REXULTI, Wegovy, KRYSTEXXA, CAPLYTA.
Industry payments across NV — which companies pay providers there.
